GlaxoSmithKline plc (GSK) is a London-based company with commercial operations in more than 150 countries, a network of 89 manufacturing sites and large R&D centres in the UK, USA, Belgium and China.
The company is involved research and development of a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare. The company recorded sales of £28 billion in 2016 an increase by 6% compared to £24 billion in 2015. The earnings per share in 2016 was 18.8p. The pharmaceutical division sales £16 billion in 2016 an increase of 3% in comparison with 2015. The growth can be attributed to the HIV products which increase by grew 37% in the year. The global growth was primarily driven by strong performances from both Triumeq (abacavir) and Tivicay (dolutegravir) products. The fiscal fourth quarter (Q4) sales were £7.6 billion, an increase of 3% compared to 2015 Q4 sales with earnings per share at 5.3p. The Q4 pharmaceutical sales was recorded at £4.6 billion, an increase of 4% compared to 2015 Q4 pharmaceuticals sales. This is due to the HIV and respiratory product growth sales. HIV sales growing 25% in the quarter. Total Respiratory sales grew 2% with 5% growth in the US and 2% growth in International. Sales of New Pharmaceutical products were £1,222 million, a Sterling increase of £602 million.
Strategic highlights: (Q4, 2016)
Opens new global vaccines R&D centre in Rockville, MD, U.S. (Dec)
Regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for belimumab, in adult patients with active, autoantibody-positive systemic lupus erythematosus. (Dec)
Submission with the EMA for once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol for patients with chronic obstructive pulmonary disease. (Dec)
Marketing Authorisation Application (MAA) to the EMA for shingles vaccine, Shingrix, for the prevention of herpes zoster in people aged 50 years or above. (Nov)
U.S. FDA for triple combination therapy fluticasone furoate/umeclidinium/vilanterol for patients with chronic obstructive pulmonary disease. (Nov).
Submitted a Biologics License Application (BLA) for its candidate shingles vaccine, ShingrixTM, to the U.S. FDA, seeking approval for the prevention of herpes zoster (shingles) in people aged 50 years or over. (Oct)
Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar Ellipta (fluticasone furoate/vilanterol) for the relief of various symptoms with chronic obstructive pulmonary disease. (Dec)
U.S. FDA’s Center for Biologics Evaluation and Research expanding the indication for FluLaval Quadrivalent (Influenza Vaccine) to include use in children 6 months and older. (Nov)
Check out all the other “Pharma Companies at a Glance” already available. Many more coming next on IgeaHub.